Stoke Therapeutics, Inc.
STOKNASDAQHealthcare● Active
$29.00
$-1.01(-3.37%)
Market Cap$1.8B
P/E Ratio—
52W High$40.22
52W Low$10.635
Stoke Therapeutics, Inc. (STOK) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
STOK · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.79
Est. -$0.80 · +1.3%
Revenue
$0.01B
Est. $0.01B · -3.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
STOK reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.73 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.80 | -$0.79 | +1.3% | $0.01B | $0.01B | -3.9% |
| ▼ Q1 FY2026 | Mar 16, 2026 | -$0.75 | -$0.97 | -29.3% | $0.00B | $0.01B | -76.0% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -$0.54 | -$0.65 | -20.4% | $0.01B | $0.00B | +133.4% |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.57 | -$0.40 | +29.8% | $0.01B | $0.01B | +158.0% |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.37 | $1.90 | +613.5% | $0.16B | $0.03B | +403.2% |
| ▲ Q1 FY2025 | Mar 18, 2025 | -$0.51 | -$0.18 | +64.7% | $0.02B | $0.00B | +485.9% |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$0.52 | -$0.47 | +9.6% | $0.00B | $0.00B | +16.5% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.73
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.79
EPS Est.
-$0.80
EPS Surpr.
+1.3%
Revenue
$0.01B
Q1 FY2026
Mar 16, 2026Miss
EPS Actual
-$0.97
EPS Est.
-$0.75
EPS Surpr.
-29.3%
Revenue
$0.00B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$0.65
EPS Est.
-$0.54
EPS Surpr.
-20.4%
Revenue
$0.01B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.40
EPS Est.
-$0.57
EPS Surpr.
+29.8%
Revenue
$0.01B
Q2 FY2025
May 13, 2025Beat
EPS Actual
$1.90
EPS Est.
-$0.37
EPS Surpr.
+613.5%
Revenue
$0.16B
Q1 FY2025
Mar 18, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.51
EPS Surpr.
+64.7%
Revenue
$0.02B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
-$0.47
EPS Est.
-$0.52
EPS Surpr.
+9.6%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.97 | $-0.81 | $-0.64 | 2 |
| Q3 FY2027 | $-1.01 | $-0.84 | $-0.67 | 2 |
| Q2 FY2027 | $-1.05 | $-0.87 | $-0.69 | 2 |
| Q1 FY2027 | $-1.05 | $-0.87 | $-0.69 | 2 |
| Q4 FY2026 | $-1.04 | $-0.86 | $-0.69 | 4 |
| Q3 FY2026 | $-0.89 | $-0.81 | $-0.74 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +1.3% | $33.28 | $32.79 | -1.47% |
| ▼ Q1 FY2026 | Mar 16, 2026 | -29.3% | $33.19 | $33.96 | +2.32% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -20.4% | $26.10 | $25.34 | -2.91% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +29.8% | $13.16 | $13.53 | +2.81% |
| ▲ Q2 FY2025 | May 13, 2025 | +613.5% | $9.66 | $8.93 | -7.56% |
| ▲ Q1 FY2025 | Mar 18, 2025 | +64.7% | $9.00 | $8.87 | -1.44% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +9.6% | $13.10 | $13.05 | -0.38% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +19.3% | $14.23 | $13.71 | -3.65% |
Q2 FY2026-1.47%
Report Date
May 7, 2026
EPS Beat/Miss
+1.3%
Price Before
$33.28
Price After
$32.79
Q1 FY2026+2.32%
Report Date
Mar 16, 2026
EPS Beat/Miss
-29.3%
Price Before
$33.19
Price After
$33.96
Q4 FY2025-2.91%
Report Date
Nov 4, 2025
EPS Beat/Miss
-20.4%
Price Before
$26.10
Price After
$25.34
Q3 FY2025+2.81%
Report Date
Aug 12, 2025
EPS Beat/Miss
+29.8%
Price Before
$13.16
Price After
$13.53
Q2 FY2025-7.56%
Report Date
May 13, 2025
EPS Beat/Miss
+613.5%
Price Before
$9.66
Price After
$8.93
Q1 FY2025-1.44%
Report Date
Mar 18, 2025
EPS Beat/Miss
+64.7%
Price Before
$9.00
Price After
$8.87
Q4 FY2024-0.38%
Report Date
Nov 5, 2024
EPS Beat/Miss
+9.6%
Price Before
$13.10
Price After
$13.05
Q3 FY2024-3.65%
Report Date
Aug 7, 2024
EPS Beat/Miss
+19.3%
Price Before
$14.23
Price After
$13.71
Avg Beat Reaction-1.95%
Avg Miss Reaction-0.30%
Beat Rate6 / 8 quarters
Largest Move-7.56% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: STOK ends December
Stoke Therapeutics, Inc. (STOK) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.79 — beating the analyst consensus of $-0.80 by +1.3%. The next STOK earnings date is expected around September 1, 2026.
Each quarter, investors track STOK earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. STOK revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
STOK's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
STOK earnings · 5 questionsStoke Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. STOK typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; STOK historically reports after market close (AMC).
STOK earnings datewhen is STOK earningsSTOK next earnings datewhen does STOK report earningsSTOK earnings calendar
▸ Source: FMP · Stoke Therapeutics, Inc. SEC filings · US GAAP · Stoke Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026